Evidence map›Paper›PMID 30070720›Full record

ArticleHepatology (Baltimore, Md.)2019

Too Stiff, Too Late . . . Timing Is Everything in Antiangiogenic Treatment of Liver Fibrosis.

Thomas Greuter, Vijay H Shah

Abstract read
In one paragraph

Article in Hepatology (Baltimore, Md.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Thomas GreuterMayo Clinic, Rochester, MN.
Vijay H ShahMayo Clinic, Rochester, MN.

Funding

Molecular Mechanisms of Portal HypertensionR01DK059615 · NIDDK · MAYO CLINIC ROCHESTER · PI SHAH, VIJAY H. · 2002 to 2023
$6.4M
TREAT-MayoU01AA021788 · NIAAA · MAYO CLINIC ROCHESTER · PI MALHI, HARMEET, SHAH, VIJAY H. · 2012 to 2022
$4.7M
Molecular Mechanisms of Liver Fibrosis (Diversity Supplement)R37AA021171 · NIAAA · MAYO CLINIC ROCHESTER · PI VIJAY H. SHAH · 2019 to 2026
$3.0M
Molecular Mechanisms of Portal HypertensionR56DK059615 · NIDDK · MAYO CLINIC ROCHESTER · PI SHAH, VIJAY H · 2007 to 2007
$378k
NIAAA NIH HHS R37 AA021171NIAAA NIH HHS U01 AA021788NIDDK NIH HHS R01 DK059615NIDDK NIH HHS R56 DK059615Novartis FoundationSwiss National Science Foundation P2ZHP3_168561
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Angiogenesis InhibitorsHumansLiver CirrhosisTime-to-TreatmentAngiogenesis Inhibitors

Identifiers

PMID30070720
PMCPMC6325014

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.